An alpha2 adrenoreceptor agonist eg. clonidine brimonidine monoxidine lofexidine is useful for the treatment of siaiorrhoea administered by the paraungual sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin glycopyrrolate ipratropium.

The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide preferably ziconotide in combination with an analgesic selected from the group consisting of morphine bupivacaine clonidine hydromorphone baclofen fentanyl buprenorphine and sufentanil or its pharmaceutically acceptable salts thereof wherein the omega-conopeptide retains its potency and is physically and chemically compatible with the ...

The present invention is directed to an implantable drug depot useful for reducing preventing or treating post-operative pain in a patient in need of such treatment the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce prevent or treat post-operative pain and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or...

An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the...

Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a matrix at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate matrix formulations are provided within biodegradable polymers, this pain relief ca...

FIELD: medicine pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents an implanted depot of a therapeutic agent for relieving preventing or treating pain in a patient in need thereof containing clonidine in the amount of 1 wt % to 15 wt % of the depot of the therapeutic agent and at least one biodegradable polymer; the above depot of the therapeutic agent has a surface that provides releasing a peak dose of clonidine in the amount of 5 wt % to 20 wt % of total amoun...

Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a matrix at or near a target site one can relieve pain caused by diverse sources including but not limited to spinal disc herniation (i.e. sciatica) spondilothesis stenosis discogenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate matrix formulations are provided within biodegradable polymers this pain relief can be co...

Disclosed is a patch which is a formulation including deposited clonidine crystals and provides stable transdermal absorbability even after storage at varying temperatures. The patch disclosed includes a backing and a medicated layer integrally superposed on one surface of the backing. The medicated layer contains: 5 to 30% by weight of clonidine including clonidine in a crystallized state